二甲双胍缓释片治疗糖耐量异常患者的有效性探究

Explore the effectiveness of melformin sustained release tablets in treatment of patients with abnormal glucose tolerance

目的采用二甲双胍缓释片治疗糖耐量异常患者,探究其对于血糖调节的有效性。方法随机选取武汉市武昌医院糖耐量异常患者78例,将其随机均分为2组。治疗组患者服用二甲双胍缓释片治疗,对照组患者仅接受常规治疗。观察并对比2组患者的葡萄糖耐量以及身体质量指数(body mass index,BMI)等指标。结果治疗组患者治疗后葡萄糖耐量试验(oral glucose tolerance test,OGTT)餐后2h为(7.61±1.04)mmol/L,对照组为(9.96±1.08)mmol/L。治疗组BMI值为23.71±3.41,对照组为29.53±3.72。治疗组糖化血红蛋白值为(5.79±0.41)%,对照组为(6.23±0.52)%。治疗组空腹血糖为(5.34±0.39)mmol/L,对照组为(8.16±0.48)mmol/L。上述指标均有显著性差异(P<0.05)。结论二甲双胍缓释片在治疗糖耐量异常患者时疗效良好。它可以有效调节患者血糖,改善其糖耐量,还能有效降低OGTT2h血糖水平和BMI值。

Objective To evaluate the effectiveness of melformin sustained release tablets in treatment of patients with abnormal glucose tolerance. Methods 78 cases with abnormal glucose tolerances were selected and divided into two groups. Patients in treatment group took melformin sustained release tablets, while patients in control group took normal therapy. The impaired glucose tolerance (IGT) and body mass index (BMI) were observed and compared. Results The blood glucose level of OGTT 2 h in treatment group was (7.61±1.04)mmol/L, while it was only (9.96±1.08) mmol/L in control group. The BMI of treatment group was 23.71±3.41, while it was 29.53±3.72 in control group. The glycosylated hemoglobin was (5.79±0.41)%, while it was (6.23±0.52)%in control group. The fasting blood glucose in treatment group was (5.34±0.39)mmol/L and in control group was (8.16±0.48)mmol/L. The differences of those indicators between two groups were signiifcant. Conclusion Melformin gains excellent clinical effects in treating patients with abnormal glucose tolerance. It can adjust blood glucose, improve glucose tolerance, and decrease blood glucose level of OGTT 2 h and BMI effectively.